What a year for microbiome science! The festive season is a good opportunity to highlight and reflect on some of the great achievements by our team and the microbiome community as a whole.
At Clinical Microbiomics, we have:
– Welcomed 10 new talented colleagues in our team
– Published 11 scientific papers with partners in academia and industry
– Completed a 10M EUR investment deal with Seventure Partners
– Acquired the expert metabolomics service provider MS-Omics, making us the world’s leading multi-omics analysis provider for the microbiome field
We are witnessing an incredible development of the microbiome field, with much interest and enthusiasm for strain engraftment analysis, multi-omics and machine learning. Last month, we all celebrated the first FDA approval for a fecal microbiota product, which will hopefully pave the way for many more microbiome-based therapeutics reaching the market and helping people live better lives.
Many thanks to our colleagues, customers, and partners for a very successful year. We wish you all wonderful holidays and a happy new year! We are looking forward to working together in 2023, for a world where people are healthier because we understand how to improve our inner ecology – the microbiome.